Recent Updates
Recently added Catalysts
Biotech Earnings Calendar
Our Biotech Earnings Calendar provides detailed earnings and forecasted estimates for covered biotech companies, featuring current EPS for informed investment decisions.
September 2026
Sun
Mon
Tue
Wed
Thu
Fri
Sat
30
31
1
+2 More
3
2
1
3
1
4
1
5
6
7
+1 More
2
8
+2 More
3
9
+3 More
4
10
+2 More
3
11
Prenetics Global
+1 More
2
12
1
13
14
+1 More
2
15
+2 More
3
16
1
17
18
1
19
20
21
+3 More
4
22
Aytu BioPharma
+2 More
3
23
+2 More
3
24
+1 More
2
25
Lite Strategy
+2 More
3
26
27
28
+4 More
5
29
1
30
1
1
2
3
: 2026-09-30
Previous EPS
: -0.89
Estimated EPS:
: -0.09
: 2026-09-03
Previous EPS
: -0.67
Estimated EPS:
: -0.06
Description
: Drug: IBIO-610. Indication: Obesity. Timeline: 2026-10-01. Full preclinical dataset from iBio's obese non-human primate study of IBIO-610 (Activin E antibody) — single-dose produced up to 98% Active Activin E inhibition and, with semaglutide, greater visceral and total fat loss — will be presented at EASD.
: 2026-09-14
Previous EPS
: -5.06
Estimated EPS:
: -0.6
Description
: Clearside Biomedical will present top line results from the ODYSSEY Phase 2b study of suprachoroidally administered CLS-AX in participants with wet AMD at The Macula Society 48th Annual Meeting. This presentation will provide insights into the efficacy and safety of CLS-AX based on the subgroup analyses conducted during the trial.
: 2026-09-14
Previous EPS
: -1.81
: 2026-09-09
Previous EPS
: 2.87
: 2026-09-09
Previous EPS
: 2.92
Estimated EPS:
: 1.1
: 2026-09-09
Previous EPS
: -1.15
Estimated EPS:
: -0.2
: 2026-09-09
Previous EPS
: -1.95
Estimated EPS:
: -0.56
Description
: Drug: detalimogene voraplasmid (detalimogene, previously EG-70). Indication: high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without concomitant papillary disease. Timeline: 2027. enGene stated a potential FDA approval for detalimogene voraplasmid could occur in 2027 following the planned BLA submission.
: 2026-09-08
Previous EPS
: -0.31
Estimated EPS:
: -0.09
Description
: Drug: liraltagene-autoleucel (lira-cel). Indication: Ovarian cancer. Timeline: September 11, 2026. Company presentation at the 2026 Cantor Fitzgerald Global Healthcare Conference on Sept 11, 2026 to discuss liraltagene-autoleucel (lira-cel), an ovarian cancer CAR-T in an ongoing Phase 1 trial; dosing has advanced to the fifth and highest cohort with lymphodepletion and four patients have surpassed one year of survival.
: 2026-09-08
Previous EPS
: -1.9
Estimated EPS:
: -0.67
Description
: Drug: AL001. Indication: healthy human subjects (pharmacokinetic imaging). Timeline: 2026-09-29. Oral presentation of first-of-its-kind 7T pharmacokinetic imaging results from the completed Phase 1/2A trial of AL001 in healthy human subjects, to be presented by Dr. Ovidiu C. Andronesi at the ISMRM X-nuclei Workshop in Barcelona on Sept 29, 2026.
: 2026-09-28
Previous EPS
: -0.19
Estimated EPS:
: -0.14
: 2026-09-28
Previous EPS
: -0.26
: 2026-09-28
: 2026-09-28
Previous EPS
: -0.23
: 2026-09-28
Previous EPS
: -4.05
Estimated EPS:
: -0.6
: 2026-09-21
Previous EPS
: -3.51
Estimated EPS:
: -1.2
Description
: Drug: BMT-801 (co-administration of bremelanotide + tirzepatide). Indication: Obesity. Timeline: later this quarter. Palatin announced completion of its Phase 2 BMT-801 study of co-administration of MC4R agonist bremelanotide with tirzepatide for obesity. Topline data from the randomized, double-blind Phase 2 trial are expected later this quarter; study enrolled 113 patients (96 randomized).
: 2026-09-21
Previous EPS
: -1.21
Estimated EPS:
: -0.28
Description
: Interim clinical data from a Phase 1b/2a study of BB-301 will be presented at the World Muscle Society Congress.
: 2026-09-21
Previous EPS
: -2.35
Description
: Drug: INM-755. Indication: small epidermal wounds. Timeline: early first quarter of calendar 2021. InMed expects to report results from the 755-102-HV Phase 1 trial of INM-755 cream, which investigated effects on small epidermal wounds, in early first quarter of calendar 2021; Study 102 recently completed subject treatment.
: 2026-09-21
Previous EPS
: -3.17
Estimated EPS:
: -0.28
: 2026-09-16
Previous EPS
: -0.08
Estimated EPS:
: -0.05
: 2026-09-10
Previous EPS
: -103.95
Description
: Drug: MTX102. Indication: Type 1 diabetes. Timeline: second half of 2016. Data updates from the MTX102 first-in-human clinical trial (innovative vaccine against type 1 diabetes, running in the UK and Sweden) are expected in the second half of 2016.
: 2026-09-10
Previous EPS
: -0.19
Estimated EPS:
: -0.05
: 2026-09-10
Previous EPS
: -2.25
Estimated EPS:
: -0.59
Lite Strategy
: 2026-09-25
Previous EPS
: -1.79
Inventiva
: 2026-09-25
Previous EPS
: -2.84
Estimated EPS:
: -0.42
Description
: Completion of recruitment for pivotal Phase III clinical trial.
Aytu BioPharma
: 2026-09-22
Previous EPS
: -3.17
Estimated EPS:
: -0.28
InMed Pharmaceuticals
Natural Alternatives Intl
: 2026-09-22
Previous EPS
: -2.29
: 2026-09-24
Previous EPS
: -1.79
: 2026-09-24
Previous EPS
: -0.45
Estimated EPS:
: -0.06
: 2026-09-01
Previous EPS
: -4.96
Estimated EPS:
: -1.25
Description
: Drug: ML-007C-MA. Indication: Schizophrenia. Timeline: H2 2026. Topline results from the Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia are expected in the second half of 2026. The trial is evaluating doses of ML-007C-MA for the treatment of hospitalized adult participants with schizophrenia experiencing an acute exacerbation of psychosis.
: 2026-09-01
Previous EPS
: 4.09
Estimated EPS:
: 1.54
: 2026-09-01
Previous EPS
: -1.3
Prenetics Global
: 2026-09-11
Previous EPS
: 4.45
: 2026-09-29
Previous EPS
: -0.45
Estimated EPS:
: -0.03
: 2026-09-23
Description
: Drug: Limbal Stem Cell (LSC) platform and derived exosome products. Indication: Dry Eye Disease. Timeline: 2026. YD Bio plans to establish a clinical-grade Limbal Stem Cell bank and submit an Investigational New Drug (IND) application to the FDA for its LSC platform and derived exosome products for Dry Eye Disease in 2026.
: 2026-09-23
Previous EPS
: -2.29
: 2026-09-04
Previous EPS
: -0.12
Description
: Drug: Plinabulin + Docetaxel (DUBLIN-3). Indication: 2nd/3rd line non-small cell lung cancer (NSCLC), EGFR wild type. Timeline: September 20, 2021. Late‑breaking oral presentation of DUBLIN-3 Phase 3 data (plinabulin + docetaxel vs. docetaxel) at ESMO on September 20, 2021, reporting the registrational study results including overall survival and key secondary endpoints.
: 2026-09-02
Previous EPS
: 2.46
Estimated EPS:
: 0.71
: 2026-09-07
Previous EPS
: -0.57
: 2026-09-12
Previous EPS
: -2.25
Estimated EPS:
: -0.59
: 2026-09-15
Previous EPS
: -2.21
Estimated EPS:
: -0.66
: 2026-09-15
Previous EPS
: -0.85
Estimated EPS:
: -0.15
Description
: Rezolute completed enrollment in the Phase 3 sunRIZE study of ersodetug in patients with congenital hyperinsulinism, with data expected to be released in the fourth quarter of 2025.
: 2026-09-18
Previous EPS
: -3.59
Estimated EPS:
: -0.12